Christian Bannister
Health data analyst from Craig Currie's group in Cardiff who works with UK primary care records, and first author of the 2014 comparison of survival in people with type 2 diabetes on metformin and people without diabetes
Human Data Sciences, Cardiff (PubMed affiliation, 2023) · Cochrane Institute of Primary Care and Public Health, School of Medicine, Cardiff University (papers 2013–2018)
Metformin is the most common first drug for type 2 diabetes, and it is being studied as a possible anti-ageing drug, partly because it acts on cell energy sensing that feeds into mTOR. In the Atlas study BAN2014, Bannister, Craig Currie and colleagues used UK primary care records to compare people with type 2 diabetes who started on metformin, people who started on a sulphonylurea, and matched people without diabetes. Those started on metformin had slightly longer median survival than the matched non-diabetic group, while those on sulphonylureas had shorter survival.
The study is observational. People prescribed metformin may differ from others in ways the records do not capture, and people who keep taking their medicine tend to be healthier in other ways too, so the result is consistent with a benefit but does not prove one.
On PubMed, Bannister's papers from 2013 to 2018 come from Cardiff University with Currie, using the Clinical Practice Research Datalink, a large UK database of anonymised GP records. They include a 2013 study showing that a widely used heart risk calculator for diabetes overestimated risk. A 2023 paper lists Bannister at Human Data Sciences in Cardiff, a company working on an online platform that turns routine health records into disease statistics.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2014 | H | Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls BAN2014 First author: analysed UK primary care records and found that people with type 2 diabetes started on metformin had slightly longer survival than matched people without diabetes. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Christian Bannister.
ShowHide
- Craig Currie Pharmacoepidemiologist at Cardiff University who uses large UK primary care databases to study diabetes treatments and their long-term outcomes, and senior author of the 2014 metformin survival study
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.